#### longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

# Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden 0.5 hours per response..

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the

Investment Company Act of 1940 (Print or Type Responses) 1. Name and Address of Reporting Person\* 5. Relationship of Reporting Person(s) to Issuer 2. Issuer Name and Ticker or Trading Symbol (Check all applicable) Salzmann Peter Corbus Pharmaceuticals Holdings, Inc. [CRBP] Director 10% Owner Officer (give title below) Other (specify below) (Middle) (Last) 3. Date of Earliest Transaction (Month/Day/Year) CORBUS PHARMACEUTICALS HOLDINGS, 05/20/2020 INC., 500 RIVER RIDGE DRIVE 4. If Amendment, Date Original Filed(Month/Day/Year) 6. Individual or Joint/Group Filing(Check Applicable Line) X\_Form filed by One Reporting Person
Form filed by More than One Reporting Person NORWOOD, MA 02062 (Zip) (City) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1. Title of Security 7. Nature 2. Transaction 2A. Deemed 3. Transaction 4. Securities Acquired 5. Amount of Securities Beneficially (Instr. 3) Date Execution Date, if Code (A) or Disposed of (D) Owned Following Reported Ownership of Indirect (Month/Day/Year) (Instr. 8) (Instr. 3, 4 and 5) any Transaction(s) Form: Beneficial Ownership (Month/Day/Year) (Instr. 3 and 4) Direct (D) (Instr. 4) or Indirect (A) or (I) Price Code Amount (D) (Instr. 4) Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. Persons who respond to the collection of information contained SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

in this form are not required to respond unless the form displays

a currently valid OMB control number.

	(e.g., puts, calls, warrants, options, convertible securities)														
Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	(Month/Day/Year)	3A. Deemed Execution Date, if	4. Transact Code	ion	5. Numb	er ntive s l (A) sed	6. Date Exer Expiration I (Month/Day	cisable and Oate (Year)	7. Title and of Underlyin Securities (Instr. 3 and	ng	Derivative Security (Instr. 5)	Derivative Securities Beneficially Owned Following Reported Transaction(s)	Derivative Security: Direct (D) or Indirect (I)	Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Exercisable	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)	(Instr. 4)	
Stock Option(right to buy) (1)	\$ 7.3	05/20/2020		A		40,500		(1)	05/20/2030	Common Stock	40,500	\$ 0	40,500	D	

#### **Reporting Owners**

		Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other			
Salzmann Peter CORBUS PHARMACEUTICALS HOLDINGS, INC. 500 RIVER RIDGE DRIVE NORWOOD, MA 02062	X						

#### **Signatures**

/s/ Peter Salzmann	05/22/2020
**Signature of Reporting Person	Date

## **Explanation of Responses:**

- If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- The option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. The option will vest in equal monthly installments over the course of 12 months beginning on the date of grant.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not re-	equired to respond unless the form displays a currently valid OMB number.